Site Map
Home
About Lipoxen
Our Technologies
Pipeline
Partnering
Corporate Governance
Investor Centre
News
Careers
FAQ
Contact us
Home
› Site Map
Site Map
Expand All
Collapse All
Home
About Lipoxen
Business Strategy
Directors
Sir Brian Richards, CBE, BSc, PhD, DSc
M Scott Maguire
Professor Gregory Gregoriadis PhD, DSc
Dr Dmitry D Genkin
Dr Tatiana Zhuravskaya, MD, PhD
Mr Colin William Hill, ACMA
Mr Firdaus Jal Dastoor, FCS
Senior Management
Sir Brian Richards, CBE, BSc, PhD, DSc
M Scott Maguire
Professor Gregory Gregoriadis PhD, DSc
Dr Peter Laing PhD
Dr Ajay K Agrawal PhD
Dr Sanjay Jain PhD
Andrew Bacon BSc
Dr Brenda McCormack PhD
Veronika Oswald
Our Technologies
PolyXen®
Publications
ImuXen®
Publications
VesicALL®
Pipeline
PolyXen® product pipeline
Polysialic EPO : ErepoXen®
Polysialic-GCSF : StimuXen™
Polysialic interferon-alpha-2b : InferoXen®
Polysialic Insulin (SuliXen®)
ImuXen® product pipeline
Liposomal Pneumococcal Vaccine : LipoNeu™
Oral Tetanus Vaccine : LipoTet™
Liposomal Hepatitis B vaccine : HepaXen™
Liposomal Rabies Vaccine : LipoRab™
VesicALL® product pipeline
Liposomal Paclitaxel : LipoTaxen™
Partnering
Corporate Governance
Investor Centre
Share Information
Share price
Investor news
Advisors
Articles of Association
FAQS
How long has Lipoxen been listed as a public company
What is the size of the market for Lipoxen's products
What is the Company's ticker symbol
Who are the Company's registrars
On what exchange are the shares traded on
When does Lipoxen report results
What is the current share price of Lipoxen plc shares
Admission Document
News
Lipoxen raises £2.6 million through Strategic Placing and Warrant Agreement with Serum Institute of India Limited
Development and Manufacturing Agreement with the Serum Institute of India Limited
Lipoxen Receives Bio Entrepreneur of the Year Award
Preliminary Results for the Year Ended 31 December 2005
Lipoxen Announces Positive Data for its ImuXen ® Liposomal Technology
Lipoxen Signs Intervet Agreement
Lipoxen's first clinical candidate, SuliXen, enters Phase I trials
Lipoxen Plc lists on AIM raising £3.78million
Change of Adviser
Lipoxen reports significant progress in the development of its DNA vaccine delivery patent portfolio
Lipoxen announces that its partner Serum Institute of India has begun Phase I trials of long-acting erythropoietin (EPO)
Sachs conference
Lipoxen Completes Technology Transfer for Sustained-Release Insulin
Lipoxen announces collaboration agreements with Baxter Healthcare & two other biopharmaceutical companies
News archive
Lipoxen reports further advancement of its DNA vaccine delivery patent portfolio
Lipoxen Announces $75M Agreement with Baxter to Develop New Blood Clotting Factors
Lipoxen Announces Positive Phase I ErepoXen Results
Lipoxen PLC Presenting at Sachs Associates
Lipoxen announces positive Phase I data with its long-acting insulin candidate, SuliXen
Lipoxen receives grant to research improved HIV vaccine delivery
Lipoxen has received approval to conduct the second Phase I trial
Canadian EPO Trial Correction
Financial Results for the 12 months ended 31 December 2007
Lipoxen Strengthens Management Team
Careers
Current job opportunities
Postdoctoral Scientists: Polymer Medicines
Register your details
FAQ
Contact us